PT Pyridam Farma Tbk

PYFA

ID1000075609

Pharmaceuticals

End-of-day quote INDONESIA S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
105 ^IDR	-3.67%		-10.26%	-90.83%

05-10	Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma	MT
03-15	PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	CI

PT Pyridam Farma Tbk and PT Pyfa Sehat Indonesia completed the acquisition of PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation for IDR 108 billion.

December 27, 2021

PT Pyridam Farma Tbk (IDX:PYFA) and PT Pyfa Sehat Indonesia entered into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation August 23, 2021.

PT Pyridam Farma Tbk (IDX:PYFA) and PT Pyfa Sehat Indonesia completed the acquisition of PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation for IDR 108 billion on December 28, 2021.

Latest news about PT Pyridam Farma Tbk

Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma	05-09	MT
PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Probiotec Enters Scheme Implementation Bid With Indonesia-Listed Pyridam Farma	12-26	MT
PT Pyridam Farma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023	10-31	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Half Year Ended June 30, 2023	31/07/23	CI
PT Pyridam Farma Tbk Reports Earnings Results for the First Quarter Ended March 31, 2023	01/05/23	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2022	05/04/23	CI
Pharmanutra S.P.A. Announces New Distribution Agreements in Indonesia, Kuwait and Mexico	04/01/23	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2022	29/11/22	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Half Year Ended June 30, 2022	30/08/22	CI
PT Pyridam Farma Tbk and PT Pyfa Sehat Indonesia entered into an agreement to acquire PT. ETHICA Industri Farmasi from Fresenius Kabi Aktiengesellschaft and Fresenius Kabi Deutschland Gmbh for IDR 163.4 billion.	12/06/22	CI
PT Pyridam Farma Tbk Reports Earnings Results for the First Quarter Ended March 31, 2022	30/05/22	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2021	08/05/22	CI
PT Pyridam Farma Tbk and PT Pyfa Sehat Indonesia completed the acquisition of PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation for IDR 108 billion.	27/12/21	CI
PT Pyridam Farma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2021	30/11/21	CI
Pt Pyridam Farma Tbk Reports Earnings Results for the Half Year Ended June 30, 2021	26/08/21	CI
PT Pyridam Farma Tbk and PT Pyfa Sehat Indonesia entered into an agreement to acquire PT Holi Pharma from Erik Darius Mardiwidyo and Murtiation.	25/08/21	CI
Pt Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2020	30/06/21	CI
Rejuve Global Investment Pte Ltd made an offer to acquire additional 16.2% stake in PT Pyridam Farma Tbk for IDX 66.8 billion.	06/09/20	CI
PT Pyridam Internasional Corporation acquired additional 29.96% stake in PT Pyridam Farma Tbk from Hasan Tjandra, Indrawati Kosasih and Lindia Kosasih for approximately IDR 120 billion.	16/07/20	CI
Pt Pyridam Farma Tbk Reports Earnings Results for the Nine Months Ended September 30, 2019	29/10/19	CI
Pt Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2018	27/03/19	CI
PT Pyridam Farma Tbk Signs Memorandum of Understanding to Form a Joint Venture with Hankook Korus Pharm Co., Ltd. to Develop a Biopharmaceutical Factory	20/11/13	CI

Chart PT Pyridam Farma Tbk

Duration

Period

More charts

Company Profile

PT Pyridam Farma Tbk is an Indonesia-based pharmaceutical company. The Company is engaged in the production, development, and trade of pharmaceuticals, as well as the trade of medical devices and cosmetics. Its segments include pharmaceutical products, esthetic, and toll manufacturing services; and medical equipments. It offers products across consumer health, pyfaesthetic, sanitizer and antiseptic, sterile/injection, biomedilab, betadine group and guardix, and medical support categories. The consumer health category provides over the counter drugs, including supplements and other preventive products, along with energy drinks and healthy ready-to-drink products. Its pyfaesthetic category includes products, such as Arosa Gel, A-Stark Gel, Hymen Gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb Gel. Its sterile/injection category is focused on injection products. Its biomedilab category provides various medical equipment and tools for hospital laboratories.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PT PYRIDAM FARMA TBK	-90.83%	71.94M
NOVO NORDISK A/S	+41.64%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+17.58%	246B
ROCHE HOLDING AG	+0.25%	225B
NOVARTIS AG	+10.50%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals